Sage remains tight-lipped on postpartum launch plans in wake of restructuring

In lay­ing off 40% of its staff and trim­ming its pipeline ear­ly Thurs­day, Sage Ther­a­peu­tics took the first step in a new di­rec­tion as it aims to launch its post­par­tum de­pres­sion drug Zurzu­vae.

This news was ex­pect­ed af­ter Sage al­lud­ed to such moves in the wake of this month’s FDA re­jec­tion of Zurzu­vae in ma­jor de­pres­sive dis­or­der (MDD), a de­ci­sion that ap­peared to take com­pa­ny lead­ers and out­side ob­servers by sur­prise. But ques­tions re­main over how Sage will ad­just its com­mer­cial strat­e­gy, how much the drug will cost and whether the com­pa­ny will con­tin­ue to pur­sue an MDD ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.